ImmunityBio Files 8-K for Shareholder Votes and Financials
Ticker: IBRX · Form: 8-K · Filed: Jun 12, 2024 · CIK: 1326110
| Field | Detail |
|---|---|
| Company | Immunitybio, Inc. (IBRX) |
| Form Type | 8-K |
| Filed Date | Jun 12, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, financial-reporting
Related Tickers: IBIO
TL;DR
IBIO filed an 8-K for shareholder votes & financials - standard stuff.
AI Summary
ImmunityBio, Inc. filed an 8-K on June 11, 2024, to report on matters submitted to a vote of security holders and financial statements. The filing details the company's corporate actions and financial reporting, with no specific new financial figures or significant events disclosed in the provided text.
Why It Matters
This filing indicates routine corporate governance and financial reporting activities for ImmunityBio, Inc., providing transparency to investors about company operations.
Risk Assessment
Risk Level: low — The filing is a routine 8-K reporting on shareholder votes and financial statements, not indicating any new material risks or events.
Key Players & Entities
- ImmunityBio, Inc. (company) — Registrant
- June 11, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 3530 John Hopkins Court (address) — Principal executive offices
- San Diego, California (location) — Principal executive offices location
- NantKwest, Inc. (company) — Former company name
- Conkwest, Inc. (company) — Former company name
- ZelleRx Corp (company) — Former company name
FAQ
What specific matters were submitted to a vote of security holders?
The filing indicates that matters were submitted to a vote of security holders, but the specific details of these matters are not provided in the excerpt.
What is the purpose of this 8-K filing for ImmunityBio, Inc.?
The purpose of this 8-K filing is to report on the submission of matters to a vote of security holders and to provide financial statements and exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on June 11, 2024.
What is ImmunityBio, Inc.'s principal executive office address?
ImmunityBio, Inc.'s principal executive office is located at 3530 John Hopkins Court, San Diego, California 92121.
What were some of ImmunityBio, Inc.'s former company names?
ImmunityBio, Inc. was formerly known as NantKwest, Inc., Conkwest, Inc., and ZelleRx Corp.
Filing Stats: 822 words · 3 min read · ~3 pages · Grade level 10.6 · Accepted 2024-06-12 16:36:10
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share IBRX The Nasdaq Global Select
Filing Documents
- ibrx-20240611.htm (8-K) — 52KB
- 0001326110-24-000069.txt ( ) — 175KB
- ibrx-20240611.xsd (EX-101.SCH) — 2KB
- ibrx-20240611_lab.xml (EX-101.LAB) — 21KB
- ibrx-20240611_pre.xml (EX-101.PRE) — 12KB
- ibrx-20240611_htm.xml (XML) — 3KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. On June 11, 2024, ImmunityBio, Inc. held its Annual Meeting of Stockholders (the "Annual Meeting"). Of the 677,036,411 shares of our common stock, par value $0.0001 per share ("Common Stock") outstanding as of April 17, 2024, 609,540,014 shares of Common Stock were represented, either by attending the Annual Meeting virtually or by proxy, constituting (i) a quorum under the company's bylaws and (ii) approximately 90% of the outstanding shares of Common Stock entitled to vote. The matters voted on at the Annual Meeting and the votes cast with respect to each such matter are set forth below. 1. Election of Nine Directors . The following nominees were re-elected by the holders of our Common Stock to serve as directors for a one year term expiring at the 2025 annual meeting of stockholders based on the following results of voting. Each director's term continues until the election and qualification of his or her successor, or until his or her earlier retirement, resignation, disqualification, removal, or death. Nominee Votes "For" Votes "Withheld" "Broker Non-Votes" Patrick Soon-Shiong, M.D. 556,206,355 6,438,677 46,894,982 Cheryl L. Cohen 561,728,022 917,010 46,894,982 Richard Adcock 561,327,002 1,318,030 46,894,982 Michael D. Blaszyk 561,317,164 1,327,868 46,894,982 John Owen Brennan 560,173,170 2,471,862 46,894,982 Wesley Clark 560,587,816 2,057,216 46,894,982 Linda Maxwell, M.D. 561,368,993 1,276,039 46,894,982 Christobel Selecky 561,329,841 1,315,191 46,894,982 Barry J. Simon, M.D. 559,237,600 3,407,432 46,894,982 2. Approval of Amendment to Increase the Number of Shares of Common Stock Authorized for Issuance under the ImmunityBio, Inc. 2015 Equity Incentive Plan . The amendment to increase the number of shares of Common Stock authorized for issuance under the company's 2015 Equity Incentive Plan by 19,900,000 shares was approved by our stockholders based on the following results of voti
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 104 Cover page interactive data file (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IMMUNITYBIO, INC. Date: June 12, 2024 By: /s/ David C. Sachs David C. Sachs Chief Financial Officer